These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 14569515)

  • 21. Prophylaxis approach to a-symptomatic post-menopausal women: breast cancer.
    Aguas F; Martins A; Gomes TP; de Sousa M; Silva DP;
    Maturitas; 2005 Nov; 52 Suppl 1():S23-31. PubMed ID: 16126355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of a model predicting enrollment status in a chemoprevention trial for breast cancer.
    Yeomans Kinney A; Vernon SW; Shui W; Weber DV; Schell M; Vogel VG
    Cancer Epidemiol Biomarkers Prev; 1998 Jul; 7(7):591-5. PubMed ID: 9681527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer risk assessment and risk reduction.
    Newman LA; Vogel VG
    Surg Clin North Am; 2007 Apr; 87(2):307-16, vii-viii. PubMed ID: 17498528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical trials with retinoids for breast cancer chemoprevention.
    Zanardi S; Serrano D; Argusti A; Barile M; Puntoni M; Decensi A
    Endocr Relat Cancer; 2006 Mar; 13(1):51-68. PubMed ID: 16601279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antihormones in prevention and treatment of breast cancer.
    Ponzone R; Biglia N; Jacomuzzi ME; Mariani L; Dominguez A; Sismondi P
    Ann N Y Acad Sci; 2006 Nov; 1089():143-58. PubMed ID: 17261763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attitudes to prophylactic surgery and chemoprevention in Australian women at increased risk for breast cancer.
    Meiser B; Butow P; Price M; Bennett B; Berry G; Tucker K;
    J Womens Health (Larchmt); 2003 Oct; 12(8):769-78. PubMed ID: 14588127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk-reducing strategies for breast cancer--a review of recent literature.
    Mokbel K
    Int J Fertil Womens Med; 2003; 48(6):274-7. PubMed ID: 15646397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress in chemoprevention of breast cancer.
    Serrano D; Perego E; Costa A; Decensi A
    Crit Rev Oncol Hematol; 2004 Feb; 49(2):109-17. PubMed ID: 15012972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endogenous hormone metabolism as an exposure marker in breast cancer chemoprevention studies.
    Kaaks R
    IARC Sci Publ; 2001; 154():149-62. PubMed ID: 11220654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Demographic and psychosocial factors associated with risk perception for breast cancer.
    Pöhls UG; Fasching PA; Beck H; Kaufmann M; Kiechle M; von Minckwitz G; Paepke S; Schultz-Zehden B; Schwarz-Boeger U; Beckmann MW
    Oncol Rep; 2005 Dec; 14(6):1605-13. PubMed ID: 16273264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits.
    Brewster AM; Christo DK; Lai H; Helzlsouer K
    Cancer; 2005 Mar; 103(6):1147-53. PubMed ID: 15674856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What information do public organizations provide to Belgian women on primary prevention of breast cancer?
    Liebens F; Aimont M; Beauraing F; Carly B; Cusumano P; Rozenberg S
    Eur J Cancer Prev; 2010 Jan; 19(1):68-70. PubMed ID: 19955905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interest in breast cancer chemoprevention among older women.
    Tjia J; Micco E; Armstrong K
    Breast Cancer Res Treat; 2008 Apr; 108(3):435-53. PubMed ID: 17554628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
    Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
    Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoprevention in postmenopausal women.
    Rastogi P
    Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthy women with a family history of breast cancer: impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal therapy decision making.
    Matloff ET; Moyer A; Shannon KM; Niendorf KB; Col NF
    J Womens Health (Larchmt); 2006 Sep; 15(7):843-56. PubMed ID: 16999640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Primary and secondary breast cancer prevention. Knowledge, assessment and participation among the female population of Schleswig-Holstein].
    Schleider SA; Schwarz-Boeger U; Jonat W; Kiechle M
    Zentralbl Gynakol; 2002 Apr; 124(4):207-12. PubMed ID: 12080482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
    Dunn BK; Ford LG
    Eur J Cancer Prev; 2007 Jun; 16(3):232-42. PubMed ID: 17415094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.